Real-World Evidence for Market Access

The same federated registry architecture used in adoption and adherence programs, pointed at the evidence a market access dossier needs.

Joint Clinical Assessment is live and widening, and sponsors need to start collecting well before filing. Registries built on running programs shorten that timeline, because the data collection is already in place.

One collection answers the medical questions alongside the access ones: how patients are characterized, which subpopulations respond, where the care pathway delays treatment, and how treatment patterns differ between countries. Medical affairs and market access work from the same dataset rather than commissioning two.

• Prospective, patient-reported data collected against a filing calendar
• Reimbursement dossiers, post-market commitments and publications from one dataset
• Patient characterization, treatment patterns and care-pathway analysis for medical affairs
• Built on the same platform as the trial and adoption work, so nothing restarts